Article · 9 Nov 2026
Conference abstract
The pharmacodynamics evaluation of SGC-003, a novel soluble guanylate cyclase agonist, on pulmonary hypertension in rats
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aim: The purpose of the present study is to evaluate the pharmacodynamics of SGC-003(Methyl-4,6-diamino-2-(1-(thien-2- yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-pyrimidin-5-ylmethylcarbamate), a novel soluble guanylate cyclase agonist, synthesized by Beijing Institute of Pharmacology and Toxicology on hypoxia and monocrotaline (MCT)-induced pulmonary hypertension in rats. Methods: The rats were exposed to chronic hypoxia (10% O2) in a ventilated chamber for three weeks or subcutaneously administrated monocrotaline (50 mg/kg) for two weeks to obtain Pulmonary Hypertension (PH) model. Pulmonary arterial pressure on anesthetized rats was measured by a blood pressure instrument. Results: In chronic treatment of hypoxia in rats, SGC-003 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, i.g., twice/day for 3 weeks) significantly inhibited the increase in the mean pulmonary arterial pressure (MPAP) (P<0.05), right ventricle systolic pressure (RVSP) (P<0.001) and right ventricular hypertrophy index (RVHI) (P<0.01) in dose-dependent manner, compared with model group, with the ratio of inhibition being 25.10%, 68.15% and 35.45%, respectively. In chronic treatment of MCT-injected rats with fully established PH, SGC-003 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, i.g., twice/day for 2 weeks) partially reversed the PH, with MPAP (P<0.05), RVSP (P<0.01) and RVHI (P<0.01), significantly decreasing in dose-dependent manner compared with model group with the ratio of inhibition being 59.82%, 55.20% and 30.19%, respectively. In addition, the experimental data from the noninvasive blood test indicated that systemic blood pressure did not significantly change after chronically administrating SGC-003 for eleven days. The above effects of SGC-003 were equivalent to BAY63-2521. Conclusion: SGC-003, a novel soluble guanylate cyclase agonist, has the inhibition effect on PH induced by hypoxia and MCT, which is equivalent to BAY63-2521. PDF HTML
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Pharmacology.
Article · 23 Feb 2026
A Thorough Overview of Polycystic Ovary Syndrome (PCOS) in Female Rats
Article · 19 Dec 2025
Theoretical Pharmacology: Understanding Drug Action Through Models and Principles
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yan Ling-Di”
- BylineArticles whose byline prints “He Zong-Sheng”
- BylineArticles whose byline prints “Dong Hua-jin”
- BylineArticles whose byline prints “Su Rui-Bin”
- BylineArticles whose byline prints “Gong Ze-Hui”
- BylineArticles whose byline prints “Zhen Zhi-Bing”
